PER-139-08已完成未知
A 24-MONTH EXTENSION FOR: A RANDOMIZED, DOUBLE BLIND, CONTROLLED PLACEBO STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF MK-0822 (KATEPSIN-K INHIBITOR) IN THE TREATMENT OF POST-MENOPAUSE WOMEN WITH OSTE
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2008年12月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 至 85（—）
- 性别
- Female
入选标准
- •The patient has met the initial inclusion criteria and has not met any of the exclusion criteria of Protocol 004-11. Note: There is no specific BMD T score required for eligibility in this extension study on Visit 18 (Month 36) or on the ISE Visit. Patients who meet the criteria for excessive bone loss should be discontinued at Visit 18 (see section 3.2.3.6 for details).
- •The patient has participated and completed the 36 months of treatment specified in Protocol 004-02 and 004-11 (which will be determined at Visit 18 / Month 36).
- •The patient generally has good health, based on medical history, physical examination and laboratory evaluation.
排除标准
- •The patient has withdrawn from Protocol 004-11 for any reason before completing the Extension of Year 3.
- •The patient presented a fractured hip, spine or other fragility fracture during previous studies (004-02 and 004-11) and would prefer to receive another therapy for osteoporosis (bisphosphonates or PTH) for which she is eligible.
- •The patient has used oral bisphosphonates in the last 6 months, IV bisphosphonates at any time, or has been treated with glucocorticoids 5 mg / day of prednisone or its equivalent) for more than 2 weeks in the last 6 months.
- •The patient has used estrogen ± progestin, raloxifene or other SERM, tamoxifen, tibolone, or an aromatase or calcitonin inhibitor in the last 6 months.
- •The patient is currently taking> 10,000 lU daily of Vitamin A (excluding beta carotene) or> 5,000 lU daily of Vitamin D.
- •The patient was diagnosed with primary parathyroid disease during previous studies (004-02 and 004-11) and has elevated PTH or a serum calcium level greater than the upper limit of the normal range.
- •The patient has hypocalcaemia as defined as serum calcium level of <8.5 mg / dL, when corrected for albumin, or shows evidence of secondary hyperparathyroidism.
- •The patient has significant clinical or laboratory abnormalities at the baseline of this extension study that, in the opinion of the researcher, could complicate the interpretation of the study results or represent an additional risk for the patient (for example, hospitalized patients should be excluded for this reason).
- •The patient suffers from cancer or presented a diagnosis of any malignancy during previous studies (004-02 and 004-11), except for squamous or basal cell skin cancer or cervical cancer in situ properly treated.
- •The patient has been treated with an agent that could have an effect on the bone, including: Current use of chemotherapy or heparin, Protease inhibitors for HIV treatment at any time, Patients are taking anticonvulsants and the rates of Calcium metabolism is not within normal limits (Note: if the calcium metabolism rates [serum calcium, serum 25-hydroxyvitamin D and serum PTH] are within normal limits, the patient can be enrolled on the basis at this criterion), Current use of systemically administered azole antifungals (for example, ketoconazole, fluconazole, itraconazole, miconazole, posaconozole, ravuconazole, and voriconazole).
- •The patient is, in the opinion of the investigator, mentally or legally incapacitated so that the informed consent cannot be obtained, or the patient cannot read or cannot understand the written material.
- •The patient has participated in the study of an investigational drug other than Protocol 004-11 within the last 30 days.
- •The patient is currently a recreational or illicit drug user or has a recent history of drug or alcohol abuse or dependence.
- •The patient demonstrates that she does not comply with the procedures required in the study.
研究者
相似试验
进行中（未招募）
1 期
A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis - Cat-K 11b Osteoporosis StudyMedDRA version: 14.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2005-001511-22-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.399
已完成
不适用
AN EXTENSION OF 12 MONTHS FOR: A RANDOMIZED, DOUBLE-BLIND, DOUBLE SIMULATOR, PARALLEL GROUP, MULTICENTRIC STUDY TO EVALUATE AND COMPARE THE EFFECTS OF ALENDRONATE AND RISEDRONATE ON BONE MINERAL DENSITY IN POSTMENUPAUSIC WOMEN WITH OSTEOPOROSIS (INTERNATIONAL FOSAMAX COMPARISON TESTS AND ACTONEL: FACT (BY ITS ACRONYMS IN ENGLISH) -INTERNATIONAL)PER-012-03MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
AN EXTENSION OF 12 MONTHS FOR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF MK-0822 (KATEATE-K INHIBITOR) IN THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH OSTEOPOROSIS-M80M80PER-074-07MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double?blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler), Tiotropium (18 µg) Inhalation Powder in the morning (gelatine capsule via Spiriva HandiHaler), Salmeterol Inhalation (25 µg) Powder in the morning and evening (PE capsule via tiotropium/salmeterol HandiHaler) and Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler) plus Salmeterol (25 µg) Inhalation Powder in the evening (PE capsule via tiotropium/salmeterol HandiHaler) in patients with COPD. - NDEUCTR2007-005107-17-ITBOEHRINGER ING.2,000
进行中（未招募）
不适用
A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder in the morning (gelatine capsule via Spiriva® HandiHaler®), Salmeterol Inhalation (25 µg) Powder in the morning and evening (PE capsule via tiotropium/salmeterol HandiHaler®) and Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder in the morning (PE capsule via tiotropium/salmeterol HandiHaler®) plus Salmeterol (25 µg) Inhalation Powder in the evening (PE capsule via tiotropium/salmeterol HandiHaler®) in patients with COPD. - 48-week comparison of Tiotropium/Salmeterol Inhalation Powder with the individual componentsChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDMedDRA version: 9.1Level: LLTClassification code 10010953Term: COPD exacerbationEUCTR2007-005107-17-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,800